argenex SE $ARGX Shares Sold by BNP Paribas Financial Markets

BNP Paribas Financial Markets cut its holdings in argenex SE (NASDAQ:ARGX) by 33.7% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 70,744 shares of the company’s stock after selling 35,970 shares during the period. BNP Paribas Financial Markets owned about 0.11% of argenex worth $59,492,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Abound Wealth Management boosted its stake in argenex by 3,200.0% during the 4th quarter. Abound Wealth Management now owns 33 shares of the company’s stock valued at $28,000 after purchasing an additional 32 shares during the period. Sound Income Strategies LLC acquired a new position in argenex during the 4th quarter valued at about $28,000. Ameriflex Group Inc. acquired a new position in argenex during the 3rd quarter valued at about $32,000. Aventura Private Wealth LLC acquired a new position in argenex during the 4th quarter valued at about $38,000. Finally, Sunbelt Securities Inc. acquired a new position in argenex during the 3rd quarter valued at about $36,000. 60.32% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research firms have issued reports on ARGX. Robert W. Baird boosted their target price on shares of argenex from $858.00 to $867.00 and gave the company a “neutral” rating in a research note on Friday, February 27th. Zacks Research raised shares of argenex from a “strong sell” rating to a “hold” rating in a research note on Friday, February 20th. Wells Fargo & Company boosted their target price on shares of argenex from $1,260.00 to $1,291.00 and gave the company an “overweight” rating in a research note on Monday. Wedbush reissued an “outperform” rating and set a $1,000.00 target price on shares of argenex in a research note on Monday, March 9th. Finally, Deutsche Bank Aktiengesellschaft raised shares of argenex from a “hold” rating to a “buy” rating in a research note on Tuesday, March 10th. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $1,019.50.

argenex Stock Down 4.1%

Shares of argenex stock opened at $802.17 on Wednesday. The firm has a market cap of $49.89 billion, a price-to-earnings ratio of 35.72, a price-to-earnings-growth ratio of 1.32 and a beta of 0.47. The business has a fifty day simple moving average of $782.33 and a 200-day simple moving average of $814.51. argenex SE has a fifty-two week low of $510.05 and a fifty-two week high of $934.62.

argenex (NASDAQ:ARGX) last announced its quarterly earnings data on Tuesday, March 31st. The company reported $5.52 earnings per share for the quarter. argenex had a return on equity of 33.28% and a net margin of 31.31%.The business had revenue of $1.31 billion during the quarter. Analysts anticipate that argenex SE will post 25.34 earnings per share for the current fiscal year.

argenex Company Profile

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.